NCT06949956Not yet recruiting
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
Administration of Fingolimod in Greek Patients With Multiple Sclerosis for the Evaluation of the Efficacy and Safety, Based on the Standard Clinical Practice.
Source: ClinicalTrials.gov · Last updated 2 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years. Participants who are already taking fingolimod as part of their regular medical care for MS will answer questions about their medical history for the past 1 year and for their status for the next 2 years.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 28 Apr 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Elpen Pharmaceutical Co. Inc.
- Diseases
- Multiple sclerosis
- NCT number
- NCT06949956
What you commit to
- Study type: Observational
- Planned participants: 140
- From 1 Jun 2025 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a contraindication to taking fingolimod according to the drug's Summary of product Characteristics (SmPC).
Other illness
- Patients with a history of mental illness, substance abuse, to a degree that may prevent their participation in the study.
Age
- Patients under 18 years of age.
Other
- Patients participating in another research protocol.
Who the study is looking for
- Patients over 18 years of age.
- Consent and compliance of participants with the treatments and procedures of the study.
- Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald 2017 criteria.
- Patients who are receiving fingolimod, according to the drug's Summary of product Characteristics (SmPC).
- Patients with available follow-up data for at least 12 months prior to their inclusion in the study, which are sufficient to calculate the annualized relapse rate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.